Tajemství vládnutí spočívá totiž v tom, jak spojit víru ve vlastní neomylnost se schopností učit se z minulých chyb.
George Orwell
Ellipticine (5,11-dimethyl-6H-pyrido[4,3-b]carbazole, Fig. 1) and its derivatives are efficient anticancer compounds that function through multiple mechanisms participating in cell cycle arrest and initiation of apoptosis (for a summary see [1-6]).
Ellipticine was found (i) to arrest cell cycle progression due to modulation of levels of cyclinB1 and Cdc2, and phosphorylation of Cdc2 in human mammary adenocarcinoma MCF-7 cells, (ii) to initiate apoptosis due to formation of toxic free radicals, stimulation of the Fas/Fas ligand system and modulation of proteins of Bcl-2 family in several tumor cell lines, and (iii) to induce the mitochondria-dependent apoptotic processes (for a summary see [3,4]). The predominant mechanisms of ellipticine’s biological effects were suggested to be (i) intercalation into DNA [5-7] and (ii) inhibition of topoisomerase II [3-6]. Further, we showed that this antitumor agent forms covalent DNA adducts after its enzymatic activation with cytochromes P450 (CYP) and peroxidases [1-4,8-13], suggesting an additional DNA-damaging effect of ellipticine. Of the CYP enzymes investigated, human CYP3A4 followed by CYP1A1 and 1B1 are the most active enzymes oxidizing ellipticine to 12-hydroxy- and 13-hydroxyellipticine, the reactive metabolites that dissociate to ellipticine-12-ylium and ellipticine-13-ylium, which bind to DNA [3,7,9-11]. The CYP1A isoforms also efficiently form the other ellipticine metabolites, 7-hydroxy- and 9-hydroxyellipticine, which are the detoxification products (Fig. 1). Recently, we found that cytochrome b5 alters the ratio of ellipticine metabolites formed by CYP1A1, 1A2 and 3A4. While the amounts of the detoxification metabolites (7-hydroxy- and 9-hydroxyellipticine) were either decreased or not changed with added cytochrome b5, 12-hydroxy-, 13-hydroxyellipticine and ellipticine N2-oxide increased considerably. The change in amounts of metabolites resulted in an increased formation of covalent ellipticine-DNA adducts, one of the DNA-damaging mechanisms of ellipticine antitumor action [11,12]. In addition, we observed that levels of the DNA adduct formed by 13-hydroxyellipticine also increased if this ellipticine metabolite was conjugated with sulfate or acetate by human sulfotransferases 1A1, 1A2, 1A3 and 2A1, or N,O-acetyltransferases 1 and 2 [11-14] as it is shown in Fig. 1. The same ellipticine-derived DNA adducts that were found in in-vitro incubations of ellipticine with DNA and enzymes activating this drug, were generated also in vivo, in several tissues of mice and rats exposed to ellipticine. In both animal models, ellipticine-DNA adduct formation was mediated mainly by CYP1A and 3A enzymes, but a role of peroxidases in several organs has been proved [15-17]. Therefore, expression levels of CYP and peroxidase enzymes metabolizing ellipticine seem to be crucial for antitumor, cytostatic and genotoxic activities of this drug in individual tissues. The ellipticine-DNA adducts were also found in several cancer cell lines and in DNA of rat mammary adenocarcinoma in vivo [3,19-25]. In this study, the utilizing the findings from several former studies [19-25] as well as new results found in this work, we evaluated whether cytotoxicity of ellipticine to cancer cells is dependent on formation of covalent ellipticine-DNA adducts and whether the expression of the enzymes metabolizing ellipticine in vitro and in vivo regulates their levels in cancer cells as well as the ellipticine cytotoxicity to these cells. The method of Western blotting determined the enzyme protein expression levels, whereas the 32P-postlabeling method detected and quantified DNA adducts formed by ellipticine [1-3,25-29].
Práce je spojená s projektem CYTORES GACR (grant P301/10/0356).
25— 2014
24— 2014
23— 2014
22— 2014
21— 2014
20— 2014
19— 2014
18— 2014
17— 2014
16— 2014
15— 2014
14— 2014
13— 2014
12— 2014
11— 2014
10— 2014
9— 2014
8— 2014
7— 2014
6— 2014
5— 2014
4— 2014
3— 2014
2— 2014
1— 2014
42— 2013
41— 2013
40— 2013
39— 2013
38— 2013
37— 2013
36— 2013
35— 2013
34— 2013
33— 2013
32— 2013
31— 2013
30— 2013
29— 2013
28— 2013
27— 2013
26— 2013
25— 2013
24— 2013
23— 2013
22— 2013
21— 2013
20— 2013
19— 2013
18— 2013
17— 2013
16— 2013
15— 2013
14— 2013
![]() | Zemědělská 1/1665 613 00 Brno Budova D | Tel.: +420 545 133 350 Fax.: +420 545 212 044 | ![]() |
![]() |